Condition: Advanced Liver Cancer · Sponsor: Binhui Biopharmaceutical Co., Ltd.
An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma
This description comes directly from the study's public registry record.
chuansheng zheng, MD · 13329702158 · 13329702158@163.com
Always discuss trial participation with your own doctor first.
| Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05698459